Discontinuation of nucleos(t)ide analog therapy in hepatitis B e antigen-negative non-cirrhotic chronic hepatitis B patients: A real-life study

doi:10.5501/wjv.120124

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 3

This Article

(9)

(8)

(0)

(195)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Virol. Sep 25, 2026; 15(3): 120124
Published online Sep 25, 2026. doi: 10.5501/wjv.120124

Table 1 Characteristics of the 87 non-cirrhotic patients with hepatitis B e antigen-negative chronic hepatitis B at the discontinuation of nucleos(t)ide analog treatment, n (%)

Variable (n = 87)
Age		40.63 (18-67)
Male		57 (65.51)
BMI (kg/m²)		23.81 (18-41)
ALT (IU/L)		87.32 (65-378)
AST (IU/L)		78.21 (44-321)
Albumin (g/dL)		39.24 (32-64)
DNA HBV (IU/L)		37211 (3210-132000)
Ishak fibrosis	F2	51 (58.62)
Ishak fibrosis	F3	36 (41.37)
NUC therapy	Entecavir	79 (90.80)
NUC therapy	Tenofovir	8 (9.20)
Time to undetectable HBV DNA (year)		5.83 (3-11)
Consolidation therapy duration (months)		46.2 (37-87)
Stiffness	< 7 kPa	21 (24.37)
Stiffness	7 kPa to 9.5 kPa	66 (75.63)
HBsAg	≤ 100 IU/mL	16 (18.31)
	101 IU/mL to 1000 IU/mL	42 (48.27)
	≥ 1000 IU/mL	29 (33.33)

BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; DNA: Deoxyribonucleic acid; HBV: Hepatitis B viral; NUC: Nucleos(t)ide analog; HBsAg: Hepatitis B surface antigen.

Full Size Table

Citation: Amalou K, Rekab R, Benmellouka N, Derbal B, Belloula A, Chetroub H, Sabrina F, Belghanem F, Saidani K. Discontinuation of nucleos(t)ide analog therapy in hepatitis B e antigen-negative non-cirrhotic chronic hepatitis B patients: A real-life study. World J Virol 2026; 15(3): 120124
URL: https://www.wjgnet.com/2220-3249/full/v15/i3/120124.htm
DOI: https://dx.doi.org/10.5501/wjv.120124

Amalou K, Rekab R, Benmellouka N, Derbal B, Belloula A, Chetroub H, Sabrina F, Belghanem F, Saidani K. Discontinuation of nucleos(t)ide analog therapy in hepatitis B e antigen-negative non-cirrhotic chronic hepatitis B patients: A real-life study. World J Virol 2026; 15(3): 120124 [PMID: 42780577 DOI: 10.5501/wjv.120124]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.